On April 18, 2024, BioVie Inc., a Nevada-based biopharmaceutical company, received notification from Nasdaq's Listing Qualifications Staff that its common stock had not met the minimum bid price of $1.00 per share over the past 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2). Consequently, BioVie has been provided a 180-day grace period, ending on October 15, 2024, to regain compliance with this requirement. The company must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days within this period to meet the continued listing standard. BioVie may be eligible for an additional grace period if it meets all other initial listing standards, except for the bid price requirement, by the deadline. Currently, the company...Show More

On April 18, 2024, BioVie Inc., a Nevada-based biopharmaceutical company, received notification from Nasdaq's Listing Qualifications Staff that its common stock had not met the minimum bid price of $1.00 per share over the past 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2). Consequently, BioVie has been provided a 180-day grace period, ending on October 15, 2024, to regain compliance with this requirement. The company must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days within this period to meet the continued listing standard. BioVie may be eligible for an additional grace period if it meets all other initial listing standards, except for the bid price requirement, by the deadline. Currently, the company meets the criteria for an extension with stockholders' equity of at least $5 million. BioVie is actively working to comply with the minimum bid price requirement; however, there is no guarantee of regaining compliance or receiving a further extension from Nasdaq. Failure to meet the standards may result in the delisting of BioVie's common stock from Nasdaq. The company's forward-looking statements indicate efforts to address these challenges but acknowledge the risks involved, including the ability to raise sufficient capital and complete clinical studies.